Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 2.5% – Here’s What Happened

Dianthus Therapeutics, Inc. (NASDAQ:DNTH)’s stock price traded down 2.5% during trading on Thursday . The company traded as low as $22.05 and last traded at $22.32. 6,067 shares traded hands during trading, a decline of 97% from the average session volume of 204,738 shares. The stock had previously closed at $22.90.

Analyst Ratings Changes

Several brokerages have recently weighed in on DNTH. Oppenheimer lifted their target price on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the company an “outperform” rating in a research report on Monday, November 11th. Raymond James upgraded Dianthus Therapeutics to a “moderate buy” rating in a research note on Thursday, December 12th. HC Wainwright restated a “buy” rating and set a $40.00 target price on shares of Dianthus Therapeutics in a research report on Monday, November 11th. Finally, TD Cowen assumed coverage on Dianthus Therapeutics in a research report on Friday, December 20th. They issued a “buy” rating on the stock. Eight investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $46.43.

Dianthus Therapeutics Price Performance

The business has a 50 day simple moving average of $25.23 and a 200 day simple moving average of $26.66. The company has a market cap of $673.04 million, a price-to-earnings ratio of -9.10 and a beta of 1.74.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.15). The company had revenue of $2.17 million for the quarter, compared to analyst estimates of $1.07 million. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. As a group, sell-side analysts anticipate that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current fiscal year.

Institutional Trading of Dianthus Therapeutics

Several hedge funds have recently modified their holdings of DNTH. Quest Partners LLC lifted its holdings in Dianthus Therapeutics by 112,400.0% during the 3rd quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock worth $31,000 after buying an additional 1,124 shares in the last quarter. SG Americas Securities LLC raised its position in shares of Dianthus Therapeutics by 104.0% during the third quarter. SG Americas Securities LLC now owns 8,839 shares of the company’s stock worth $242,000 after acquiring an additional 4,506 shares during the last quarter. The Manufacturers Life Insurance Company acquired a new position in shares of Dianthus Therapeutics during the second quarter valued at $236,000. Fred Alger Management LLC increased its position in Dianthus Therapeutics by 52.5% in the third quarter. Fred Alger Management LLC now owns 9,633 shares of the company’s stock worth $264,000 after purchasing an additional 3,316 shares during the period. Finally, WINTON GROUP Ltd acquired a new stake in shares of Dianthus Therapeutics during the 2nd quarter worth approximately $265,000. 47.53% of the stock is owned by institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.